Research Output
Optimising Adoptive T Cell Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation
  Allogeneic hematopoietic stem cell transplantation (HSCT) is carried out to correct genetic disorders of the hematopoietic system, as well as to treat hematopoietic malignancies. Adoptive Tcell therapy has great potential as an adjunct to this treatment modality, and clinical trials have already demonstrated the feasibility and efficacy of this approach. It offers two therapeutic effects in this setting:
(1) Augmentation of anti-tumor responses, such as in the setting of relapsed disease; (2) Prevention and treatment of transplant-related infections.
Underlying the therapeutic efficacy of adoptive T cell therapy is the demonstration of a graft-vs-leukemia/lymphoma (GvL) effect

  • Date:

    01 January 2010

  • Publication Status:

    Published

  • Publisher

    World Scientific

  • DOI:

    10.1142/9789814271271_0016

  • Funders:

    University College London

Citation

Ghorashian, S., Wright, G., Thomas, S., Hart, D. P., King, J., Voisine, C., …Stuass, H. J. (2010). Optimising Adoptive T Cell Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation. In Y. Reisner, & M. F. Martelli (Eds.), Bone Marrow Transplantation Across Major Genetic Barriers. , (373-395). United Kingdom: World Scientific. https://doi.org/10.1142/9789814271271_0016

Authors

Monthly Views:

Available Documents